A Randomized, Double-Blind, Vehicle-Controlled, Parallel, Phase II Study to Evaluate Efficacy and Safety of BAC in Patient With Alzheimer's Disease or Vascular Dementia
Not yet recruiting
Phase of Trial: Phase II
Latest Information Update: 26 Jul 2017
At a glance
- Drugs CSTC 1 (Primary)
- Indications Alzheimer's disease; Vascular dementia
- Focus Therapeutic Use
- Sponsors Charsire Biotechnology Corporation
- 26 Jul 2017 Last checked against ClinicalTrials.gov record.
- 18 Jul 2017 Planned initiation date changed from 1 Mar 2017 to 1 Dec 2017.
- 17 Apr 2017 New trial record